Archives
-
Calpain Inhibitor II, ALLM for Protease Research
2026-09-13
Calpain Inhibitor II, ALLM is a cell-permeable, broad cysteine-protease tool for connecting calpain and cathepsin activity with apoptosis, FAK stability, and tumor-cell behavior. Its strongest use is comparative pathway testing: combine dose-response studies with cleavage, viability, and rescue assays rather than interpreting cytotoxicity as calpain-2-specific evidence.
-
TCEP Hydrochloride and Smarter LFA Sensitivity
2026-09-12
A translational analysis of how TCEP hydrochloride could support disulfide-triggered capture-and-release architectures in lateral flow assays, with emphasis on mechanism, assay compatibility, evidence boundaries, and practical development strategy.
-
Elbasvir–Grazoprevir: Evidence for HCV Treatment
2026-09-11
This literature-focused review examines how complementary NS5A and NS3/4A inhibition underpins elbasvir–grazoprevir therapy for chronic hepatitis C. The reference paper integrates pharmacology, pharmacokinetics, clinical efficacy, resistance, safety, and special-population evidence, with particularly strong support for HCV genotype 1 and 4 infections.
-
ONX-0914 (PR-957) Workflow for Immune Studies
2026-09-11
ONX-0914 (PR-957) provides a selective way to interrogate LMP7-driven immune signaling without treating the constitutive β5 proteasome as the primary target. This article translates new extracellular-vesicle findings into practical cytokine, cell-transfer, arthritis research, and diabetes research workflows, with optimization points for compound handling and assay interpretation.
-
Lopinavir: From HIV Protease to Translational Strategy
2026-09-10
Lopinavir (ABT-378) illustrates how mechanism-led compound selection can connect HIV protease biology with broader antiviral discovery. This article examines its resistance-aware potency, serum-context behavior, assay design considerations, pharmacokinetic implications, and the limits of interpreting cross-pathogen cell-culture findings.
-
Thrombin B Chain Fragment: Assay Workflow Guide
2026-09-10
Use this defined human thrombin B-chain peptide as a sequence-controlled reagent for binding, mass-spectrometry, and fibrin-related assay development—not as an assumed replacement for intact catalytic thrombin. The workflow combines careful reconstitution, matched controls, orthogonal readouts, and reference-study principles for distinguishing genuine protease effects from nonspecific assay artifacts.
-
From SHP2 Mutations to Stable Plant Proteomes
2026-09-09
Mechanistic studies of SHP2 show how subtle conformational changes can reshape signaling and disease interpretation. This thought-leadership article connects that lesson to plant cell protein stability, explaining why broad-spectrum protein degradation inhibition and disciplined extract handling are strategic requirements for translational research.
-
Calpain Inhibitor I, ALLN: Practical Lab Guide
2026-09-09
Calpain Inhibitor I, ALLN (SKU A2602) is a DMSO-soluble cysteine-protease inhibitor for experiments examining calpain and cathepsin involvement in apoptosis, inflammation, and ischemia-reperfusion injury. Use it with vehicle controls and orthogonal readouts; it is not intended for diagnostic, therapeutic, or medical applications, and its multi-protease profile limits single-target interpretation.
-
HDAC Inhibitors Repress NUT Carcinoma Function
2026-09-08
Shiota et al. developed a dCAS9-based chemical screen that identified structurally diverse HDAC inhibitors as suppressors of NUT-dependent transcription in NUT carcinoma. The study connects HDAC inhibition with BRD4-NUT megadomain disruption, tumor-cell differentiation, and improved xenograft control when combined with bromodomain inhibition.
-
AEBSF.HCl in Protease and Necroptosis Workflows
2026-09-08
AEBSF.HCl provides irreversible, broad-spectrum serine protease control for cell lysates, APP-processing experiments, and leukemic cell-lysis models. Its strongest value is as a practical perturbation and sample-protection reagent, provided researchers distinguish serine-protease effects from the cathepsin-centered mechanism of necroptosis.
-
Z-VDVAD-FMK in Apoptosis Pathway Research
2026-09-07
Z-VDVAD-FMK helps researchers separate caspase-2-associated mitochondrial apoptosis from caspase-independent and pyroptotic death. This practical guide connects inhibitor handling, assay design, pathway-specific readouts, and troubleshooting for cancer research and mechanistic cell-death studies.
-
CPI-613: A Metabolism-to-Immunity Research Framework
2026-09-07
CPI-613, also known as 6,8-bis(benzylsulfanyl)octanoic acid, links mitochondrial bioenergetics to tumor–immune communication. This article translates recent PDHA1 succinylation findings into practical decisions for apoptosis assays, tumor cell metabolism studies, and combination-treatment experiments.
-
Tofacitinib citrate: Reliable Cell Assays
2026-09-05
This scenario-based guide explains how Tofacitinib citrate (CP-690550 citrate), SKU A4135, can support interpretable viability, proliferation, and inflammatory-cell assays. It combines formulation guidance, concentration selection, controls, and literature-based cautions for JAK-STAT and endothelial research.
-
Proteinase K for DNA and EV Workflows
2026-09-04
Proteinase K combines broad protein digestion with compatibility across common molecular-biology buffers, making it useful for genomic DNA isolation and controlled extracellular-vesicle surface assays. This guide translates its practical strengths into executable workflows while showing how the Candida albicans EV study can inform assay controls without overstating what the paper tested.
-
Z-VAD-FMK in Cell-Death Mechanism Studies
2026-09-04
Z-VAD-FMK helps researchers distinguish caspase-dependent apoptosis from alternative forms of regulated cell death in immune, epithelial, and cancer models. Its greatest value emerges when pharmacological inhibition is paired with time-resolved viability, caspase activity measurement, and orthogonal pathway readouts.